Vulnerability · CVE-2026-31841
Hyperterse is a tool-first MCP framework for building AI-ready backend surfaces from declarative config.
Published Mar 12, 2026 · catalog updated Jun 17, 2026 · Hyperterse is a tool-first
Check if you run it
No confirmed exploitation is on record for CVE-2026-31841. EPSS is 0.30%. Act only if a listed version of Hyperterse is a tool-first is installed.
Gaps on this record
- The stored product name is a package slug. The name on this page is taken from the title (Hyperterse is a tool-first).
- No version range is stored. A customer cannot check an installed version against this record.
- No vendor fix or required action is stored. Compare the linked advisory before you change production.
- Severity
- Medium6.5
- Known exploitation
- Not in CISA/VulnCheck KEV
- EPSS
- 0.30%
- Remediation
- Advisory link
- Affected products
- cpe hyperterse/hyperterse
Hyperterse is a tool-first MCP framework for building AI-ready backend surfaces from declarative config. Prior to v2.2.0, the search tool allows LLMs to search for tools using natural language. While returning results, Hyperterse also returned the raw SQL queries, exposing statements which were supposed to be executed under the hood, and protected from being displayed publicly. This issue has been fixed as of v2.2.0.
Are you affected?
Enter the version you run. The result uses only the ranges stored on this record.
The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.
- cpe hyperterse/hyperterseversion unspecified
How to fix CVE-2026-31841
Recommended remediation
A patch or advisory reference is linked. Open the original publisher for availability by product version.
Official advisories
What to do
Three questions, each answered from this record only. Confirm the vendor advisory before you patch.
Should you patch?
No confirmed exploitation is on record for CVE-2026-31841. EPSS is 0.30%. Act only if a listed version of Hyperterse is a tool-first is installed.
Which versions are affected?
Affected version ranges are not on this record. Compare the installed version with the linked vendor advisory before you change production.
What should an analyst verify?
CWE-433. EPSS 0.30%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.
Code
The project this record applies to. Exploit listings stay in References.
Timeline
Detection, updates, and resolution for this record.
Mar 12, 2026 · NIST NVD
Detected
Hyperterse is a tool-first MCP framework for building AI-ready backend surfaces from declarative config. Prior to v2.2.0, the search tool allows LLMs to search for tools using natural language. While returning results, Hyperterse also returned the raw SQL queries, exposing statements which were supposed to be executed under the hood, and protected from being displayed publicly. This issue has been
Jun 17, 2026 · NIST NVD
Updated
Hyperterse is a tool-first MCP framework for building AI-ready backend surfaces from declarative config. Prior to v2.2.0, the search tool allows LLMs to search for tools using natural language. While returning results, Hyperterse also returned the raw SQL queries, exposing statements which were supposed to be executed under the hood, and protected from being displayed publicly. This issue has been
Sources
- CVE.orgVulnerability recordCVE-2026-31841
Official CVE identifier
cve.org - FIRST EPSSExploitation probabilityCVE-2026-31841
30-day exploitation probability 0.3%
first.org - NIST NVDVulnerability recordCVE-2026-31841
Hyperterse is a tool-first MCP framework for building AI-ready backend surfaces from declarative config. Prior to v2.2.0, the search tool allows LLMs to search for tools using natural language. While returning results, Hyperterse also returned the raw SQL queries, exposing statem
nvd.nist.gov
References
Freshness
Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.